Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
2.29 x 19 2.37 x 10
Pre-market by (Cboe BZX)
2.28 -0.26 (-10.24%) 03/24/25 [NASDAQ]
2.29 x 19 2.37 x 10
Pre-market 2.28 unch (unch) 16:00 ET
Quote Overview for Mon, Mar 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.25
Day High
2.61
Open 2.60
Previous Close 2.54 2.54
Volume 1,374,600 1,374,600
Avg Vol 721,870 721,870
Stochastic %K 18.47% 18.47%
Weighted Alpha -72.41 -72.41
5-Day Change -0.27 (-10.59%) -0.27 (-10.59%)
52-Week Range 2.25 - 11.20 2.25 - 11.20
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,480
  • Shares Outstanding, K 63,807
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,950 K
  • EBIT $ -74 M
  • EBITDA $ -75 M
  • 60-Month Beta 0.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.81

Options Overview Details

View History
  • Implied Volatility 282.47% ( +171.42%)
  • Historical Volatility 82.37%
  • IV Percentile 91%
  • IV Rank 47.05%
  • IV High 547.34% on 03/06/25
  • IV Low 47.07% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,226
  • Volume Avg (30-Day) 172
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 5,897
  • Open Int (30-Day) 5,686

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 4
  • High Estimate -0.25
  • Low Estimate -0.36
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -14.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +1.33%
on 03/24/25
Period Open: 3.03
3.19 -28.53%
on 03/07/25
-0.75 (-24.75%)
since 02/24/25
3-Month
2.25 +1.33%
on 03/24/25
Period Open: 3.78
4.27 -46.60%
on 01/03/25
-1.50 (-39.68%)
since 12/24/24
52-Week
2.25 +1.33%
on 03/24/25
Period Open: 8.09
11.20 -79.64%
on 07/16/24
-5.81 (-71.82%)
since 03/22/24

Most Recent Stories

More News
Larimar: Q4 Earnings Snapshot

Larimar: Q4 Earnings Snapshot

LRMR : 2.28 (-10.24%)
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

LRMR : 2.28 (-10.24%)
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

LRMR : 2.28 (-10.24%)
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

LRMR : 2.28 (-10.24%)
Larimar Therapeutics Reports Positive Initial Data from Nomlabofusp OLE Study for Friedreich’s Ataxia

Larimar Therapeutics reports positive results from nomlabofusp study for Friedreich’s ataxia, showing increased frataxin levels and potential clinical benefits.Quiver AI SummaryLarimar Therapeutics announced...

LRMR : 2.28 (-10.24%)
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

LRMR : 2.28 (-10.24%)
Larimar Therapeutics Presents Promising Data on Nomlabofusp at International Congress for Ataxia Research, Showing Potential to Enhance Frataxin Levels in Friedreich's Ataxia Patients

Nomlabofusp shows potential to improve frataxin levels and lipid profiles in Friedreich’s ataxia patients, with further studies planned.Quiver AI SummaryLarimar Therapeutics presented data on its treatment...

LRMR : 2.28 (-10.24%)
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

LRMR : 2.28 (-10.24%)
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 59.47 (+1.38%)
TBPH : 9.39 (unch)
MDGL : 346.40 (+1.40%)
LRMR : 2.28 (-10.24%)
CPRX : 25.74 (+6.23%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 59.47 (+1.38%)
TBPH : 9.39 (unch)
MDGL : 346.40 (+1.40%)
LRMR : 2.28 (-10.24%)
CPRX : 25.74 (+6.23%)

Business Summary

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

See More

Key Turning Points

3rd Resistance Point 2.87
2nd Resistance Point 2.74
1st Resistance Point 2.51
Last Price 2.28
1st Support Level 2.15
2nd Support Level 2.02
3rd Support Level 1.79

See More

52-Week High 11.20
Fibonacci 61.8% 7.78
Fibonacci 50% 6.72
Fibonacci 38.2% 5.67
Last Price 2.28
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals